{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:23:13Z","timestamp":1792570993927,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jdiacomp.2025.109021","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T19:12:56Z","timestamp":1743275576000},"page":"109021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus"],"prefix":"10.1016","volume":"39","author":[{"given":"Hasan Fehmi","family":"\u00d6zel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e\u00fcheda","family":"Alpay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Asker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif S\u0131dal","family":"G\u00fcltekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Kazda\u011fl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109021_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus","volume":"21","author":"Suzuki","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/FJC.0000000000001099","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors in heart failure: an updated systematic review and meta-analysis of 13 randomized clinical trials including 14,618 patients with heart failure","volume":"78","author":"Shrestha","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0020","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-019-0853-x","article-title":"Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials","volume":"18","author":"Yang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0030","doi-asserted-by":"crossref","unstructured":"R. Roy et al., \u201cSodium-glucose cotransporter-2 (SGLT-2) inhibitors in heart failure: an umbrella review,\u201d Cureus, vol. 15, no. 7, 2023, Accessed: Feb. 10, 2025. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10436676\/.","DOI":"10.7759\/cureus.42113"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0040","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/diab.39.10.1177","article-title":"Heart-rate variability and cardiac autonomic function in diabetes","volume":"39","author":"Malpas","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0045","first-page":"17","article-title":"The crosstalk between autonomic nervous system and blood vessels","volume":"10","author":"Sheng","year":"2018","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.18087\/cardio.2022.6.n2049","article-title":"Triglyceride glucose index is related with cardiac autonomic dysfunction in patients with metabolic syndrome","volume":"62","author":"Balc\u0131o\u011flu","year":"2022","journal-title":"Kardiologiia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0055","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2337\/db16-0437","article-title":"Cardiac autonomic function is associated with the coronary microcirculatory function in patients with type 2 diabetes","volume":"65","author":"von Scholten","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0060","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2337\/db18-1313","article-title":"Cardiac autonomic function is associated with myocardial flow reserve in type 1 diabetes","volume":"68","author":"Zobel","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fpubh.2017.00258","article-title":"An overview of heart rate variability metrics and norms","volume":"5","author":"Shaffer","year":"2017","journal-title":"Front Public Health"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0070","first-page":"323","article-title":"Heart rate variability and heart rate turbulence in patients with polycystic ovary syndrome","volume":"16","author":"\u00d6zke\u00e7eci","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0075","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155243","article-title":"SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study","volume":"137","author":"Sardu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/FJC.0000000000001176","article-title":"Current perspectives of the use of sodium\u2013glucose transport-2 inhibitors for patients with heart failure and chronic kidney disease","volume":"79","author":"Vider","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0090","first-page":"10","article-title":"The effect of SGLT2 inhibitor therapy on endothelial progenitor cell function in patients with heart failure","author":"Kakzanov","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/jocmr2385w","article-title":"Sodium-glucose cotransporter 2 inhibitors: possible anti-atherosclerotic effects beyond glucose lowering","volume":"8","author":"Yanai","year":"2015","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jcph.1998","article-title":"Association between the use of sodium-glucose cotransporter-2 inhibitors and drug-induced acute kidney injury: analysis of 2 databases","volume":"62","author":"Satoru","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.107949","article-title":"Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D)","volume":"35","author":"Ang","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2020.100039","article-title":"Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis","volume":"7","author":"Garg","year":"2020","journal-title":"Metab Open"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0120","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/HJH.0000000000002480","article-title":"Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes","volume":"38","author":"van Bommel","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0125","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/dme.14279","article-title":"Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance","volume":"37","author":"Nojima","year":"2020","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-804766-8.00008-X","article-title":"Autonomic dysfunction: diagnosis and management","volume":"167","author":"Rafanelli","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-024-02185-3","article-title":"Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle Diabetes Study Phase II","volume":"23","author":"Davis","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0140","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03007995.2022.2027141","article-title":"Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? \u2013 targeting hyperinflammation","volume":"38","author":"Alshnbari","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/oxfordjournals.eurheartj.a014868","article-title":"Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","volume":"17","author":"Malik","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(89)90436-0","article-title":"Comparison of time- and frequency domain-based measures of cardiac parasympathetic activity in Holter recordings after myocardial infarction","author":"Bigger","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1515\/tjb-2024-0046","article-title":"Right vagotomy alters heart rate variability temporarily and increases total choline levels in rats","volume":"49","author":"Kazdagli","year":"2024","journal-title":"Turk J Biochem"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0165","doi-asserted-by":"crossref","first-page":"858","DOI":"10.55730\/1300-0144.5383","article-title":"Classical heart rate variability and nonlinear heart rate analysis in mice under Napentobarbital and ketamine\/xylazine anesthesia","volume":"52","author":"Kazda\u011fl\u0131","year":"2022","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0170","first-page":"6677","article-title":"The effects of mechanical ventilation on heart rate variability and complexity in mice","volume":"74","author":"Kazda\u011fli","year":"2023","journal-title":"J Hell Vet Med Soc"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0175","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/acd254","article-title":"A simple approach to determine loss of physiological complexity in heart rate series","volume":"9","author":"Ozel","year":"2023","journal-title":"Biomed Phys Eng Express"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1152\/ajpheart.00405.2000","article-title":"Poincar\u00e9 plot interpretation using a physiological model of HRV based on a network of oscillators","volume":"283","author":"Brennan","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0185","doi-asserted-by":"crossref","DOI":"10.1023\/A:1015212328405","article-title":"Approximate entropy of heart rate variability: validation of methods and application in heart failure","author":"Beckers","year":"2001","journal-title":"Cardiovasc Eng Int J"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0190","doi-asserted-by":"crossref","DOI":"10.1063\/1.166141","article-title":"Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series","author":"Peng","year":"1995","journal-title":"Chaos"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphys.2019.00115","article-title":"A fast DFA algorithm for multifractal multiscale analysis of physiological time series","volume":"10","author":"Castiglioni","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0200","first-page":"317","article-title":"Nonlinear methods to assess changes in heart rate variability in type 2 diabetic patients","volume":"101","author":"Roy","year":"2013","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/jod.jod_17_18","article-title":"Can decreased heart rate variability be a marker of autonomic dysfunction, metabolic syndrome and diabetes?","volume":"10","author":"Trivedi","year":"2019","journal-title":"J Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0210","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.3390\/ijms22084215","article-title":"Obesity, nutrition and heart rate variability","volume":"22","author":"Str\u00fcven","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/DMSO.S123935","article-title":"Association between obesity and heart rate variability indices: an intuition toward cardiac autonomic alteration - a risk of CVD","volume":"10","author":"Yadav","year":"2017","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195166","article-title":"Heart rate variability in type 2 diabetes mellitus: a systematic review and meta\u2013analysis","volume":"13","author":"Benichou","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0225","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-07-0090","article-title":"Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes","author":"Gonz\u00e1lez-Clemente","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0230","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00592-020-01482-z","article-title":"Diminished heart rate variability in type 2 diabetes is exacerbated during exercise-heat stress","volume":"57","author":"Macartney","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0235","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0245","doi-asserted-by":"crossref","unstructured":"K. Chonko, G. Russo-Alvarez, D. Isaacs, L. Wang, and A. Soric, \u201cPrevalence of sodium glucose cotransporter 2 (SGLT-2) inhibitor prescribing in patients with type 2 diabetes mellitus and reduced estimated glomerular filtration rate,\u201d Innov. Pharm., vol. 14, no. 2, 2023, Accessed: Feb. 19, 2025. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10653713\/.","DOI":"10.24926\/iip.v14i2.5456"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00592-022-01958-0","article-title":"Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"60","author":"Patoulias","year":"2023","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s001250051609","article-title":"Silent coronary artery disease in diabetes - a feature of autonomic neuropathy or accelerated atherosclerosis?","volume":"44","author":"Airaksinen","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0260","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0275","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","article-title":"Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk","volume":"9","author":"Goncalves","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0280","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0285","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0002-9149(99)00066-1","article-title":"Heart rate variability in obesity and the effect of weight loss","volume":"83","author":"Karason","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0290","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0300","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0310","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0315","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0320","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0325","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0330","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.clinthera.2022.09.002","article-title":"Cardiac autonomic neuropathy in type 1 and 2 diabetes: epidemiology, pathophysiology, and management","volume":"44","author":"Williams","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002480","article-title":"Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis","volume":"9","author":"Chowdhury","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0340","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/DMSO.S129797","article-title":"Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives","volume":"10","author":"Fisher","year":"2017","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/2251-6581-12-55","article-title":"Association of cardiac autonomic neuropathy with arterial stiffness in type 2 diabetes mellitus patients","volume":"12","author":"Bagherzadeh","year":"2013","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5374176","article-title":"Cardiac autonomic neuropathy: why should cardiologists care about that?","volume":"2017","author":"Bissinger","year":"2017","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0355","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4239\/wjd.v6.i1.80","article-title":"Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment","volume":"6","author":"Balc\u0131o\u011flu","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0360","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.106.634949","article-title":"Diabetic cardiovascular autonomic neuropathy","volume":"115","author":"Vinik","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0365","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.4022\/jafib.2400","article-title":"The \u2018road\u2019 to atrial fibrillation: the role of the cardiac autonomic nervous system","volume":"13","author":"Malik","year":"2020","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0370","first-page":"295","article-title":"Impact of exercise on cardiovascular autonomic neuropathy","volume":"30","author":"Saldarriaga","year":"2023","journal-title":"Rev Colomb Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0375","doi-asserted-by":"crossref","unstructured":"S. Z. Sudo, T. L. Montagnoli, B. de S. Rocha, A. D. Santos, M. P. de S\u00e1, and G. Zapata-Sudo, \u201cDiabetes-induced cardiac autonomic neuropathy: impact on heart function and prognosis,\u201d Biomedicines, vol. 10, no. 12, p. 3258, 2022.","DOI":"10.3390\/biomedicines10123258"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0380","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fendo.2013.00173","article-title":"Tests for early diagnosis of cardiovascular autonomic neuropathy: critical analysis and relevance","volume":"4","author":"Rolim","year":"2013","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0385","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/dmrr.1239","article-title":"Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management","volume":"27","author":"Spallone","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0390","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00125-024-06242-0","article-title":"Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.992327","article-title":"Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial","volume":"9","author":"Karalliedde","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0400","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i\u2014Arrhythmias and Sudden Cardiac Death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0405","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.239","article-title":"Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice","volume":"4","author":"Hatanaka","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0410","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13098-015-0044-1","article-title":"Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation","volume":"7","author":"Nakamura","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3971060","article-title":"Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus","volume":"2019","author":"Mirabelli","year":"2019","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17512433.2019.1588110","article-title":"Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies","volume":"12","author":"Singh","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0425","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cvr\/cvz323","article-title":"Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes","volume":"116","author":"Heuvelman","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0430","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0435","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0440","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/08037059409102293","article-title":"The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men","volume":"3","author":"Gudbj\u00f6rnsdottir","year":"1994","journal-title":"Blood Press"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0445","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjhyper.2003.11.006","article-title":"Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration","volume":"17","author":"Manzella","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0450","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2796.2005.01531.x","article-title":"Metformin improves endothelial function in patients with metabolic syndrome","volume":"258","author":"Vitale","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0455","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0735-1097(01)01129-9","article-title":"Improved endothelial function with metformin in type 2 diabetes mellitus","volume":"37","author":"Mather","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0460","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3389\/fimmu.2019.01050","article-title":"DPP-4 inhibitors as potential candidates for antihypertensive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdiacomp.2025.109021_bb0465","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/med.21513","article-title":"Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection","volume":"39","author":"Tomovic","year":"2019","journal-title":"Med Res Rev"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:52:03Z","timestamp":1744401123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1056872725000741"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109021","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109021"}}